- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
CMS OKs pegaptanib reimbursement rate
Washington, DC—The Centers for Medicare & Medicaid Services has announced that as of Jan. 1, 2005, the Medicare Part B allowable for pegaptanib sodium (Macugen, Eyetech Pharmaceuticals) is 106% of average sales price (ASP), or $1,054.70 per injection.
Washington, DC-The Centers for Medicare & Medicaid Services has announced that as of Jan. 1, 2005, the Medicare Part B allowable for pegaptanib sodium (Macugen, Eyetech Pharmaceuticals) is 106% of average sales price (ASP), or $1,054.70 per injection. The drug was approved by the FDA in December for use in the treatment of wet age-related macular degeneration. Eyetech and Pfizer launched pegaptanib sodium on Jan. 20, 2005.
For more information, go to http://www.cms.hhs.gov/providers/drugs/asp.asp and download the document called Jan 2005 ASP Pricing File and ASP NOC Pricing File.
